Does Ozempic Also Help with Anxiety and Depression? Understanding New Research and Genuine Opinions on Social Media

Do GLP-1 Drugs Also Benefit the "Heart"? A New Study Raises Significant Questions

The discourse surrounding GLP-1 receptor agonists has significantly evolved over the past few years. Initially focused on diabetes treatment, the spotlight then shifted to obesity treatment and weight loss effects. Now, the discussion is advancing even further, prompted by a study using large-scale data from Sweden. Tracking records from 2009 to 2022 of 95,490 individuals with anxiety disorders or depression who were using diabetes medications, the study found that during periods when GLP-1 drugs, particularly semaglutide, were used, there was less "deterioration of mental state" compared to periods when they were not used.

In this study, "deterioration of mental state" does not refer to self-reported changes like feeling slightly down or vaguely anxious. It is a metric that encompasses relatively severe outcomes such as hospitalization due to mental illness, sick leave for mental reasons, self-harm, or suicide. Thus, the study does not simply suggest that "GLP-1 drugs lift moods," but rather indicates the possibility that, at least for some individuals, there were fewer instances of severe mental health deterioration. Misinterpreting this could significantly distort the study's meaning.

Looking at the numbers alone, the impact is indeed significant. Semaglutide was associated with a 42% lower risk of overall mental state deterioration, a 44% lower risk of depression worsening, and a 38% lower risk of anxiety disorder worsening. Additionally, the risk of substance use disorder worsening was 47% lower. While liraglutide also showed an 18% reduction, no significant decrease was observed with exenatide or dulaglutide. This indicates that not all GLP-1 drugs are the same, and differences between medications are apparent.

So why did these results emerge? Although still in the hypothesis stage, several pathways are being considered. Weight loss and improved blood sugar control may alter self-assessment and bodily sensations, potentially suppressing the worsening of anxiety and depression. A reduction in cravings for alcohol and other dependencies could lead to mood and lifestyle stabilization. Furthermore, GLP-1 might affect not only appetite but also brain circuits related to reward systems, satiety, and impulsivity. The narrative of "quieting food noise" from those affected likely describes these changes in brain and behavior in layman's terms.

In fact, posts about this "mental quietness" are quite prominent on social media. On Reddit, users report that since using GLP-1 drugs, they have stopped constantly thinking about food, feel calmer, and have reduced dependency and anxiety. Research analyzing public posts also extracts themes of increased self-esteem and hope, improved feelings of anxiety and depression, reduced compulsive behaviors, and decreased alcohol consumption. While experiences shared on social media do not constitute medical proof, they cannot be ignored as they highlight "lived experiences" that are hard to capture in clinical settings.

However, the reactions on social media are not all hopeful. Other posts and online review analyses confirm voices saying "I felt more depressed," "my anxiety worsened," or "life became tough due to nausea and fatigue." Qualitative research on Reddit shows cases where aversion to food and loss of enjoyment in eating lead to anxiety and a sense of loss, and JMIR's analysis also notes some users reporting worsening depressive symptoms. This means that even with the same drug, there are those whose minds become quieter and those whose physical and mental distress increases, and understanding must encompass this range of experiences.

Moreover, a recurring theme on social media is the issue of "whether it can be continued" rather than the drug itself. Shortages, insurance coverage, out-of-pocket costs, approval barriers, and societal prejudice. Reddit research highlights major themes of access barriers, anxiety over insurance lapses, and shame or criticism for using the drug. A PLOS discussion also points out that while GLP-1 drugs expand demand in a society anxious about weight, they may exacerbate disparities and stigma. Even if the body changes with the drug, the societal gaze surrounding it does not necessarily change. In fact, excessive attention to weight loss and moral judgments of "relying on drugs" can become new stressors.

The most important point here is that this study is observational. Experts emphasize that while a correlation was shown, causation has not been proven. The design comparing the same individual's "during use" and "non-use" periods is a strength, but it still cannot fully explain details of weight changes, symptom severity, or life background. Therefore, it is premature to assert that "GLP-1 drugs are treatments for depression and anxiety." Rather, this study is closer to a starting line, suggesting the value of progressing to future randomized controlled trials.

The debate over safety also continues. In March 2026, the US FDA requested the removal of warning labels regarding increased risk of suicidal ideation and behavior for GLP-1 receptor agonists, stating that no increase was confirmed. On the other hand, in 2025, the EMA concluded that semaglutide could very rarely cause a serious eye disorder called NAION, indicating a frequency of about 1 in 10,000. This means that while perspectives on mental aspects are becoming somewhat positive, overall safety monitoring of the drugs has not ended.

Nevertheless, the significance of this study is not small. GLP-1 drugs are emerging as potentially having "broad effects" that extend beyond merely reducing weight, potentially involving appetite, reward, addiction, self-image, and life restructuring. The realization shared on social media that "a life overwhelmed by thoughts of food has become a bit quieter" reveals changes that numbers alone cannot convey. However, this quietness does not come to everyone, and costs, side effects, continuity concerns, and societal scrutiny can become new burdens. What is needed now is neither enthusiasm nor denial. It is the hope that it might work and caution about what is not yet proven. With both in mind, we need to observe over a longer time frame what this drug brings to people's minds and behaviors.

Source URL

・Global News. Summarizes key points of the study published in Lancet Psychiatry, including the number of subjects, risk reduction rates, limitations of being an observational study, and related safety issues.
https://globalnews.ca/news/11739505/glp1-anxiety-depression-mental-health-study/

・Introduction to the study by Karolinska Institutet. Used to confirm the number of subjects, tracking period, differences between drugs, and the need for clinical trials due to the observational nature of the study.
https://news.ki.se/diabetes-drug-ozempic-linked-to-better-mental-health

・The Lancet Psychiatry article page. Used to confirm the study title and main results.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2826%2900014-3/fulltext

・Expert comments from the Science Media Centre. Used to understand how to interpret observational studies, the inability to yet determine causation, and the clinical positioning of the study.
https://www.sciencemediacentre.org/expert-reaction-to-observational-study-on-glp-1-receptor-agonists-and-lower-risk-of-worsening-mental-illness-as-published-in-the-lancet-psychiatry/

・FDA safety information (March 2026). Used to confirm the latest regulatory authority information stating that no increase in risks of suicidal ideation and behavior was confirmed for GLP-1 receptor agonists.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp

・FDA's ongoing evaluation page. Used to confirm the cautious expression that small risks have not been completely ruled out as of the initial evaluation in 2024.
https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type

・EMA safety announcement. Used to confirm the European judgment that semaglutide and NAION are "very rare side effects."
https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy

・Qualitative research published in PMC. Used to organize trends in SNS reactions from Reddit posts by Wegovy users, including increased self-esteem, reduced drinking, access anxiety, stigma, loss of enjoyment in food, and anxiety.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12327412/

・JMIR paper. Used to confirm that satisfaction is more influenced by "whether it worked" than by side effects themselves, with some reports of worsening depressive symptoms.
https://www.jmir.org/2026/1/e78391

・PLOS Global Public Health paper. Used to organize the broader social context of how GLP-1 drugs relate to social stigma, disparities, and belief formation through SNS.
https://journals.plos.org/globalpublichealth/article?id=10.1371%2Fjournal.pgph.0005516

・Scientific American article. Used as supplementary background understanding of how GLP-1 drugs might relate to appetite, reward systems, and addictive behaviors, and the concept of "food noise."
https://www.scientificamerican.com/article/ozempic-quiets-food-noise-in-the-brain-but-how/

・Reddit post (mounjarouk). Used to confirm the temperature difference in public SNS reactions to the study news, such as "calmed down," "reduced dependency and anxiety," and "heard stories of worsening."
https://www.reddit.com/r/mounjarouk/comments/1rydphi/study_reveals_glp1_medications_may_ease_symptoms/

・Reddit post (loseit). Referenced as a public SNS post showing how the term "food noise" has been shared among affected individuals.
https://www.reddit.com/r/loseit/comments/173rr2f/recently_i_learned_about_food_noise_and_it_blows/